• A combination of AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy has extended overall survival (OS) when used as a first-line treatment for stage IV (metastatic) non-small cell lung cancer (NSCLC).

• A final analysis of data from the POSEIDON Phase 3 study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone.

• The trial also tested a combination of Imfinzi plus chemotherapy, which, while showing a statistically significant improvement in progression-free survival (PFS) versus chemotherapy, failed to improve OS significantly.

• Each combination demonstrated an acceptable safety profile, and no new safety signals were identified.

• The data will be presented at a forthcoming medical meeting.

• Price Action: AZN shares are up 0.62% at $53.81 during the market trading session on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Biden Administration Backs Waiving IP Protections For COVID-19 Vaccines, Pharma Industry Rebukes Move

• Single Shot Of AstraZeneca, Pfizer COVID-19 Vaccines Provide 87% Protection, South Korea Study Shows: Reuters

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.